


Isolere Bio Enters into Agreement with Aldevron to Develop a Scalable Manufacturing Process for IsoTag Reagents

DURHAM, NC, USA, October 11, 2021 /EINPresswire.com/ -- October 7, 2021 – [Isolere Bio](#), a biotech firm working to develop a low-cost, high throughput, and scalable purification platform, has entered into an agreement with [Aldevron](#), a leading research to GMP biomanufacturer of plasmid DNA, mRNA, and proteins, to develop a low-cost manufacturing strategy for its IsoTag™ reagents, that is able to easily scale up to meet demand for an industry that is seeing tremendous growth and bottleneck pressures.



The hallmark of Isolere's mission is to deliver transformative manufacturing processes that accelerate development and improve the global accessibility of viral vectors and other complex biologics. A critical piece in realizing this vision is ensuring a stable and low-cost supply of high

quality IsoTag™ reagents. The decades-long lag in innovation of downstream manufacturing technologies has caused significant bottlenecks in the manufacturing of the viral vectors used in cell and gene therapies, as well as vaccines. IsoTag uses a simple recombinant reagent that is easy to produce and is easily plugged into existing downstream processes using conventional filtration equipment and validated, off-the-shelf consumables.

“

I'm excited about our partnership with Isolere, as together, we can leverage strengths to develop a highly differentiated manufacturing technology with the potential to disrupt the current paradigm”

Tom Foti

“While Isolere has had significant traction with end users seeking to evaluate the IsoTag™ technology, security of supply is an important component in adoption of our

technology”, said Kelli Luginbuhl, Ph.D., Founder and Chief Executive Officer of Isolere. “Aldevron's commitment to supplying the industry with high quality raw materials is an

important piece of Isolere's plan for bringing IsoTag™ to market. We could not ask for a better partner to help us drive this innovation towards commercial success. Aldevron's reputation for excellence in raw material and critical reagent supply will help bring Isolere's technology closer to clinical and commercial implementation."

"I'm very excited about our partnership with Isolere Bio, as together, we can leverage strengths to develop a highly differentiated manufacturing technology with the potential to disrupt the current paradigm," said Tom Foti, President of Aldevron's Protein Business Unit. "A key driver for this collaboration is to decrease the healthcare cost of life-saving therapies that require AAV and large molecule therapeutics. A protein that can be manufactured at large scale in Aldevron's GMP facilities is key to realizing this vision."

About Isolere Bio

Isolere Bio, Inc. is a privately held, emerging bioprocessing company developing a transformative platform technology for the next generation manufacturing of complex biologics. The company has deep expertise in the phase separation phenomena evolved by nature to perform highly specific separations in complex environments. Isolere's development and application of phase separating proteins is backed by decades of research and high-impact publications by the company's Co-Founders and Chief Scientific Officer. Isolere is based in North Carolina in the United States.

<https://www.isolerebio.com/>

MEDIA CONTACT: press@isolerebio.com

INVESTOR CONTACT: kluginbuhl@isolerebio.com

About Aldevron

Aldevron is a premier manufacturing partner in the global genetic medicine field. Founded in 1998 by Michael Chambers and John Ballantyne, the company provides critical nucleic acids and proteins used to make gene and cell therapies, DNA and RNA vaccines, and gene editing technologies. Aldevron's 700+ employees support thousands of scientists who are developing revolutionary treatments for millions of people.

Media Contact for Aldevron:

Ellen Shafer

Senior Director of Marketing and Communications

ellen.shafer@aldevron.com

701.297.9256

Kelli Luginbuhl

Isolere Bio

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/553326506>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.